Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India

Autor: Peta RK, Panchal HP, Patel A, Parikh S, Khanikar D, Himthani N
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Journal of Medical and Scientific Research, Vol 8, Iss S1, Pp 6-10 (2020)
Druh dokumentu: article
ISSN: 2321-1326
2394-112X
DOI: 10.17727/JMSR.2020/8S1-1
Popis: Background: Coronavirus disease 2019 (COVID-19) is a pandemic caused by a novel beta coronavirus severe acute respiratory syndrome coronavirus (SARS-CoV-2). The symptoms range from mild to severe in nature. The severity of respiratory symptoms is due to the cytokine storm. The tocilizumab, interleukin-6 inhibitor, can prevent the cytokine release and decrease the mortality. Patients and methods: This is a retrospective observational study of 20 COVID-19 positive cases who received tocilizumab. Results and conclusion: There were 75% males with a mean age of 47.20±9.68 years in our study. 50% had diabetes mellitus, 35% had hypertension, 5% had Chronic kidney disease, 5% had obesity and 5% had hypothyroidism. Mortality was reduced to 65% with tocilizumab administration. There was statistically significant reduction of C- reactive protein (p
Databáze: Directory of Open Access Journals